NEW YORK, Oct. 14, 2025 – Pfizer Inc. (NYSE: PFE) announced positive topline results from the Phase 3 HER2CLIMB-05 trial, evaluating TUKYSA® (tucatinib) in combination with trastuzumab and pertuzumab as first-line maintenance therapy for HER2-positive (HER2+) metastatic breast cancer (MBC). The trial met its primary endpoint, showing a statistically significant and clinically meaningful improvement in progression-free survival (PFS) compared to placebo with standard maintenance therapy following chemotherapy induction.
Science Significance
HER2+ breast cancer affects 15–20% of patients and is associated with poor prognosis and rapid disease progression. Historically, first-line maintenance therapy following induction has remained unchanged since 2012. HER2CLIMB-05 demonstrates that adding TUKYSA can further delay disease progression, offering a potential new standard for patients who complete initial chemotherapy-based therapy. “This trial shows that TUKYSA may reduce the risk of progression or death in HER2+ MBC patients,” said Dr. Erika Hamilton, principal investigator. The treatment was well-tolerated, with a safety profile consistent with previous studies, supporting its use in the first-line maintenance setting.
Regulatory Significance
Currently approved for use in combination with trastuzumab and capecitabine in later-line HER2+ MBC, TUKYSA has not yet been approved for first-line therapy. HER2CLIMB-05 results provide critical evidence for regulatory discussions that could lead to expanded approval for first-line maintenance, creating the first chemotherapy-free maintenance option for these patients. Regulatory authorities are expected to review these findings, which may accelerate availability for a broader patient population, addressing a key unmet medical need.
Business Significance
Advertisement
Since its 2020 approval, TUKYSA has become a standard of care in third-line HER2+ MBC in over 50 countries. The HER2CLIMB-05 results could expand its use to first-line therapy, increasing the eligible patient population and commercial impact. Pfizer emphasizes strategic opportunity in offering a chemotherapy-sparing maintenance option, which may enhance adoption and position TUKYSA as a frontline solution. “The results underscore TUKYSA’s potential role in first-line maintenance and its benefit for a broader patient population,” said Johanna Bendell, Chief Development Officer, Oncology, Pfizer.
Patients’ Significance
For patients, TUKYSA in combination with trastuzumab and pertuzumab offers a new avenue to prolong progression-free survival without additional chemotherapy. The trial reinforced that adverse events were manageable, with diarrhea and hepatotoxicity being the most common but mostly mild to moderate. By potentially delaying disease progression, this therapy may improve quality of life and reduce treatment burden, offering hope for patients facing a historically aggressive disease.
Policy Significance
If approved, TUKYSA as first-line maintenance could reshape clinical practice and treatment guidelines for HER2+ MBC. Oncology societies and healthcare policymakers may update recommendations to include a chemotherapy-free maintenance strategy, enhancing access to evidence-based, tolerable therapies. This aligns with broader efforts to personalize therapy, optimize patient outcomes, and reduce treatment toxicity in metastatic breast cancer care.
Transaction Highlights
HER2CLIMB-05 was a randomized, double-blind, placebo-controlled Phase 3 study designed to evaluate TUKYSA as first-line maintenance therapy in patients with HER2+ metastatic breast cancer who had completed induction therapy with trastuzumab, pertuzumab, and a taxane and showed no evidence of disease progression. A total of 654 patients were enrolled, with 326 patients receiving TUKYSA in combination with trastuzumab and pertuzumab, and 328 patients receiving placebo with trastuzumab and pertuzumab. The primary endpoint of the trial was progression-free survival (PFS) as assessed by investigators, which was met, demonstrating a statistically significant and clinically meaningful improvement in patients treated with TUKYSA compared to placebo. Overall survival, a key secondary endpoint, is under ongoing evaluation. Safety data were consistent with previous studies, with diarrhea occurring in 81% of patients, though only 1% required treatment discontinuation. Hepatotoxicity led to discontinuation in 1.5% of patients. Other common adverse events included palmar-plantar erythrodysesthesia, nausea, vomiting, and rash. Importantly, TUKYSA was generally well-tolerated, with most side effects manageable and consistent with the known safety profile of the therapy. These results indicate that TUKYSA has the potential to become a new standard for first-line maintenance therapy in HER2+ metastatic breast cancer, offering patients a chemotherapy-sparing option that can delay disease progression while maintaining a favorable safety profile. Full data from HER2CLIMB-05 will be presented at upcoming medical congresses and discussed with regulatory authorities.
Source: Pfizer Inc. Press Release
